LeMaitre Vascular (LeMaitre Vascular) Risk Assessment

View and export this data going back to 2006. Start your Free Trial

What is LeMaitre Vascular Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of LeMaitre Vascular is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of LeMaitre Vascular's Risk Assessment

For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LeMaitre Vascular's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Risk Assessment distribution charts can be found below:

* The bar in red indicates where LeMaitre Vascular's Risk Assessment falls into.

LeMaitre Vascular (NAS:LMAT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

LeMaitre Vascular Risk Assessment Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

LeMaitre Vascular (LeMaitre Vascular) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

LHU:Germany

Address

63 Second Avenue, Burlington, MA, USA, 01803

Website

https://www.lemaitre.com

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Executives

George W Lemaitre	director, 10 percent owner, officer: Chairman, President and CEO	342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
Bridget A Ross	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
John A Roush	director	C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Lawrence J Jasinski	director	SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
David B Roberts	director, officer: CFO and Director	55 BRADFORD STREET, NEEDHAM MA 02492
Trent G Kamke	officer: Senior V. P., Operations	61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Pellegrino Joseph P Jr	officer: Executive V.P. Finance	68 BEACON STREET, BOSTON MA 02108
Michael H Thomas	director	P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer	officer: President, International OP	AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas	officer: VP of Sales, The Americas	C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W	director, officer: V.P., Human Resources,Director	8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays	director	C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden	officer: VP, North American Sales	236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr	director	HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199